Home
Ncardia

Ncardia Market Share Analysis for August 2026

Ncardia offers a range of human iPSC-derived cardiac and neural cell models that can be used in drug discovery.

Science and Education > Biology

Domainncardia.com

Year Founded2011

Employees51 - 200

Annual Revenue$15M - $25M

Ncardia

Ncardia (including company regionals)

ncardia.com

See more website traffic and engagement information

Ncardia Revenue up to August 2026 is 15M - 25M

revenue generated by Ncardia top domains

Ncardia top domains revenue over 3 years

Revenue for Ncardia top domains

ncardia.com15M - 25M

See more with Sales Intelligence

Total visits to Ncardia's top domains

Understand Ncardia market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ncardia.com3.7K

See more with Sales Intelligence

Avg. visit duration in Ncardia's top domains

Analyze Ncardia engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ncardia.com00:00:11

See more with Sales Intelligence

Avg. pageviews on Ncardia's top domains

See how Ncardia keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ncardia.com1.60

See more with Sales Intelligence

Ncardia top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Ncardia

These are the website technologies, by industry, used by Ncardia top domains

Advertising (6)

DoubleClick

Conversion & Analytics (5)

Google Analytics

Payment & Currencies (5)

Cart Functionality

Marketing (4)

Google Marketing Platform

More Technologies

13

See all

News & Signals from Ncardia

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNcardia launched Ncyte NHP-C vCardiomyocytes on Sep 23rd '25.Ncardia, a leader in stem cell - based solutions for drug discovery and safety assessment, today announced the launch of Ncyte(R) NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys.

NewsNcardia launches panel of ready-to-use assays.Ncardia launches panel of ready-to-use assays to streamline screening and selection of new therapeutic candidates.

NewsNcardia launched comprehensive drug discovery platform for therapeutic research in obstructive hypertrophic cardiomyopathy on Apr 1st '20.For instance, in April 2020, Ncardia launched a comprehensive drug discovery platform for therapeutic research in obstructive hypertrophic cardiomyopathy (HCM).